Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

NEW YORK, Jan 12, 2026, 14:43 EST — Regular session

  • Shares of Abercrombie & Fitch tumbled following the company’s downgrade of its full-year sales growth forecast
  • Company revised its holiday-quarter outlook and highlighted tariff expenses baked into its guidance
  • Investors are eyeing this week’s ICR Conference for new insights on demand and pricing

Shares of Abercrombie & Fitch Co dropped 17.3% to $103.26 in afternoon trading Monday, following a cut to its full-year sales growth forecast and a more cautious holiday-quarter outlook. The stock had climbed as high as $124.75 earlier before falling to a session low of $98.87.

The reset came as apparel and footwear companies rolled out early holiday-quarter updates, highlighting a tougher consumer environment ahead of the ICR Conference. Consumer Edge analyst Michael Gunther noted that “value-seeking behavior was on full display” in this morning’s wave of retail pre-announcements, with shoppers— even those with higher incomes—continuing to favor cheaper options. Abercrombie’s forecast for roughly 5% sales growth in the fourth quarter falls short of the 5.8% increase that analysts had predicted, according to LSEG data cited by Reuters. (Reuters)

For Abercrombie, it wasn’t the magnitude of the revision that mattered as much as the fact it moved downward. Investors had priced in steady growth and flawless execution; so even a minor cut can sting when expectations are so high.

Abercrombie now forecasts fiscal 2025 net sales growth of at least 6%, down slightly from its previous 6% to 7% range, with an operating margin near 13% and earnings between $10.30 and $10.40 per share. For Q4, the company expects sales growth around 5% and earnings in the $3.50 to $3.60 per share range. It raised planned capital spending to roughly $245 million, while maintaining share repurchase plans at about $450 million for the year, including $100 million this quarter. The outlook factors in approximately $90 million in tariff expenses—equivalent to 170 basis points, or 1.7 percentage points, of sales after mitigation—and a $39 million pretax gain from a litigation settlement. CEO Fran Horowitz described quarter-to-date net sales through fiscal December as “record.” (SEC)

The margin line looks set to come under pressure next. Operating margin—which measures operating profit as a portion of sales—can shift rapidly when retailers ramp up promotions to drive traffic.

The risk here is clear. The company’s tariff calculations rely on trade policies from early January; any major changes in policy, enforcement, or new supply-chain issues could trigger yet another adjustment.

Investors will want to see how much of the profit forecast hinges on one-time items. The litigation settlement adds a lift to the full-year outlook, but it’s a one-off. Some portfolio managers will likely exclude it from their calculations.

Following that, the ICR Conference in Orlando runs through Jan. 14. Investors usually use this event to dig into retailers’ demand, pricing, and sourcing strategies. Fresh insights on tariffs or early January sales could nudge Abercrombie shares in one direction or another for the week ahead. (Icrconference)

Stock Market Today

  • Morgan Stanley spotlights three key humanoid robot parts suppliers amid Tesla's pivot
    February 1, 2026, 9:36 PM EST. Tesla's shift from electric cars to humanoid robots heightens demand for specialized parts. Morgan Stanley names Shanghai-listed Leaderdrive, Shenzhen's Inovance Technology, and Jiangsu Hengli Hydraulic as top suppliers positioned to profit. Leaderdrive saw its 2025 profit forecast double, reflecting growing production as clients move beyond prototypes. Inovance focuses on affordable linear actuators needed for robot motion, anticipating rising adoption in 2026-27. Hengli, supplying screws for robot assemblies, expects humanoids to form a larger revenue slice next year. Morgan Stanley doubled its China humanoid sales estimate this year to 28,000 units, noting that component production often precedes actual sales, signaling early industry scale-up.
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk
Previous Story

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026
Next Story

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Go toTop